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The objective of the present study was to identify the single photon
emission computed tomography (SPECT) and magnetic resonance
(MR) findings in juvenile systemic lupus erythematosus (JSLE) pa-
tients with CNS involvement and to try to correlate them with neuro-
logical clinical history data and neurological clinical examination.
Nineteen patients with JSLE (16 girls and 3 boys, mean age at onset
9.2 years) were submitted to neurological examination, electroen-
cephalography, cerebrospinal fluid analysis, SPECT and MR. All the
evaluations were made separately within a period of 15 days. SPECT
and MR findings were analyzed independently by two radiologists.
Electroencephalography and cerebrospinal fluid analysis revealed no
relevant alterations. Ten of 19 patients (53%) presented neurological
abnormalities including present or past neurological clinical history
(8/19, 42%), abnormal neurological clinical examination (5/19, 26%),
and abnormal SPECT or MR (8/19, 42% and 3/19, 16%, respectively).
The most common changes in SPECT were cerebral hypoperfusion
and heterogeneous distribution of blood flow. The most common
abnormalities in MR were leukomalacia and diffuse alterations of
white matter. There was a correlation between SPECT and MR
(P<0.05). We conclude that SPECT and MR are complementary and
useful exams in the evaluation of neurological involvement of lupus.
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Introduction
In 16 to 52% of the patients with juvenile
systemic lupus erythematosus (JSLE), a wide
spectrum of neuropsychiatric manifestations
may occur at any time during the course of
the disease (1-7). The diagnosis of neuro-
logical involvement in JSLE is usually diffi-
cult due to the low sensitivity of the comple-
mentary exams. Among these, computed to-
mography (CT) and magnetic resonance
(MR) should be highlighted, both being use-
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ful in the detection of anatomical alterations
of the central nervous system (CNS). More
recently, single photon emission computed
tomography (SPECT) has been used to evalu-
ate cerebral perfusion in children with lupus
(8,9). Szer et al. (8), studying five JSLE
patients with severe clinical signs of neuro-
logical involvement, observed SPECT ab-
normalities in all of them, but MR alterations
in only three. Reiff et al. (9) also studied the
SPECT and MR of ten JSLE patients with
CNS involvement and found abnormal
SPECT changes in all patients and MR alter-
ations in six of ten patients.
The purpose of the present study was to
identify the SPECT and MR findings in JSLE
patients with CNS involvement and to try to
correlate them with neurological clinical his-
tory data and neurological clinical examina-
tion.
Patients and Methods
Nineteen patients (16 girls and 3 boys)
were selected consecutively at the pediatric
rheumatology outpatient clinic of a univer-
sity hospital. The inclusion criteria were di-
agnosis of JSLE according to the classifica-
tion criteria of the American College of Rheu-
matology (1982) (10) and age under 16 years.
Consent to participate in the study was ob-
tained from parents or persons responsible
for each child or adolescent. The research
was approved by the Hospital Ethics Com-
mittee.
Mean age at onset was 9.2 years and
mean disease duration until the time of the
investigation was 4.2 years. During the study,
12 patients (63%) presented some degree of
clinical lupus activity, including malar rash,
vasculitis, arthritis and nephritis. Fifteen pa-
tients were receiving steroids and 14 were
receiving immunosuppressive drugs (azathio-
prine, methotrexate or cyclophosphamide)
at the time of the SPECT and MR investiga-
tion.
All selected patients were submitted to
neurological clinical history, neurological
examination, electroencephalography, cere-
brospinal fluid analysis, SPECT, and MR.
Demographic and clinical data were obtained
by a pediatric rheumatologist. Parents/pa-
tients were asked about the neuropsychiatric
manifestations which had been observed
since the onset of the disease. A pediatric
neurologist performed neurological exami-
nation. Any neurological abnormality found
in routine neurological exams, including signs
of pyramidal or extrapyramidal involvement,
and cerebellar, upper cortical function, neu-
romuscular, or peripheral abnormalities was
considered to be “neurological abnormal-
ity”.
Single photon emission computed
tomography
All patients received an intravenous in-
jection of 99mtechnetium-ethylenedicystein-
ate-dimer (99mTc-ECD) at the dose of 740-
1110 MBq (20-30 mCi), with scanning of
the images being initiated after 10 to 15 min.
A gamma camera equipped with a single
rotating head was used. The images were
scanned with a 64 x 64 matrix, without zoom,
with 6º angles, comprising 360º, for a total of
60 images, with a scanning time of 20 s per
angle and total time of 20 min. The images
were fed into a computer and reconstructed
by applying a recovery filter (Butterworth)
with a cut frequency of 0.25 and a threshold
of 4, in the axial, sagittal and coronal projec-
tions with a thickness of 0.9 cm, presented
later on the screen for interpretation. The
images were analyzed by three independent
investigators. The examination was consid-
ered normal when there was a symmetrical
and homogeneous concentration of 99mTc-
ECD in both cerebral hemispheres, and ab-
normal in the presence of asymmetry in the
distribution of the 99mTc-ECD in the whole
hemisphere or in some lobe, and/or when
there were focal areas of low tracer concen-
tration. The examinations were considered
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normal if they demonstrated increased activ-
ity in the occipital cortex (visual). This find-
ing is considered to be an artifact or a varia-
tion of normal data.
Magnetic resonance
The exam was carried out in two stages,
i.e., with and without contrast. Scanning was
performed on 5-mm thick sagittal, axial and
coronal slices using a Philips Gyroscan S 15
instrument of 1,5 Tesla. In the phases with
and without contrast, the sagittal slices were
scanned in T1 with a relaxation time (RT) of
775 ms and an echo time (ET) of 20 ms. The
axial slices were scanned with proton den-
sity in T2 with RT between 2500 and 3000
ms and ET between 30 and 90 ms, and in T1,
with the same patterns as the sagittal images.
The paramagnetic contrast used was
Magnevistan® (dimegluminic gadopentetate,
1 ml-469 mg; Schering, São Paulo, SP, Bra-
zil). The MR images were independently
analyzed by two radiologists who were not
aware of patient clinical history or diagnosis.
Complementary tests
All patients were submitted to electroen-
cephalography and cerebrospinal fluid anal-
ysis, both performed by a neurologist.
Statistical analysis
The Kappa value was calculated to evalu-
ate the concordance among the imaging
exams (11) and the Spearman correlation
coefficient was used to correlate the neuro-
logical clinical history/patient neurological
clinical examination with SPECT and MR
findings (12). Two-tailed tests were used,
with the alpha probability fixed at 5%.
Results
Electroencephalography and cerebrospi-
nal fluid analysis were normal. Ten of 19
patients (53%) presented neurological ab-
normalities including present or past neuro-
logical clinical history (8/19, 42%), abnor-
mal neurological clinical examination (5/19,
26%), and abnormal SPECT (8/19, 42%) or
MR (3/19, 16%). History, neurological clini-
cal examination, SPECT and MR findings
are presented in Table 1.
The most common changes observed in
the SPECT were cerebral hypoperfusion (Fig-
ure 1A) and heterogeneous distribution of
blood flow (Figure 1B). The most common
MR abnormalities were leukomalacia (Fig-
ure 1C) and diffuse alterations of white mat-
ter.
We observed a significant correlation
between SPECT and MR (P = 0.032, Spear-
man correlation coefficient). The Kappa test
also showed a correlation between the imag-
ing exams (Z = 2.477, P<0.02).
Discussion
The neurological clinical history and ex-
amination are still considered to be the “gold”
standard for the determination of CNS in-
volvement in JSLE patients. In the present
study, the neurological clinical history was
positive in 8/19 patients; however, in two
patients who presented abnormalities in both
SPECT and MR (patients #8 and #9, Table
1), no neurological sign or symptom was
observed. Our findings are in agreement with
those reported by Russo et al. (13). In their
study, SPECT was performed on 30 JSLE
patients, 20 of them presenting positive clini-
cal CNS involvement. Diffuse SPECT ab-
normalities were observed in 50% of the
patients without clinical signs of CNS in-
volvement. Falcini et al. (14) studied the
SPECT of 14 JSLE patients and detected
abnormalities in 2/7 patients without neuro-
logical clinical signs or symptoms. After 6
months, SPECT was performed again on the
same patients and signs of imaging improve-
ment were observed. These findings suggest
that some JSLE patients may present sub-
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Table 1. Past and present neurological clinical history, neurological clinical examination, single photon
emission computed tomography (SPECT) and magnetic resonance (MR) of JSLE patients who have pre-
sented some degree of CNS involvement since the onset of the disease (N = 10).
Patient # Age at onset History Neurological SPECT MR
(years)/gender clinical
examination
1 8/F Behavior Tremor Hypoperfusion of left Normal
alteration frontoparietal lobe
2 11/F Transverse Normal Normal Normal
myelitis,
chorea, CVA
3 8/F CVA, chorea Decrease of Hypoperfusion of Leukomalacia of right
muscular strength left frontoparietal temporofrontoparietal
and deep reflexes lobe and right lobe, cerebellar and
(left side)    parietal lobe cortical atrophy
4 9/M Headache Tremor Hypoperfusion of right Normal
temporal lobe and
heterogenous flow
5 7/F Seizures Tremor Hypoperfusion of left Normal
temporofrontoparietal
lobe
6 10/F Seizures Paresthesia Normal Normal
7 8/M Headache, Normal Hypoperfusion of left Focal leukomalacia of
nystagmus, temporoparietal lobe parietal lobe
CVA, facial (posterior), cortical
palsy atrophy
8 11/F Normal Normal Hypoperfusion of left Diffuse abnormalities
temporoparietal lobe of white matter,
and heterogenous cerebellar and cortical
flow atrophy
9 8/F Seizures Normal Hypoperfusion of left Normal
frontoparietal lobe
10 12/F Normal Normal Heterogenous flow Normal
F = female, M = male, CVA = cerebrovascular accident.
Figure 1. Most common
changes observed in the
SPECT: cerebral hypo-
perfusion (A) and hetero-
geneous distribution of
blood flow (B). The most
common MR abnormali-
ties were leukomalacia
(C) and diffuse alter-
ations of white matter.
A B C
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clinical CNS involvement which can be de-
tected by SPECT.
Some literature reports have demonstrated
an agreement between the clinical and SPECT
findings (8,9,15,16). Reiff et al. (9) studied
11 JSLE patients, all of them with active
neurological disease, and observed SPECT
alterations in 100% of cases. These investi-
gators concluded that SPECT is sensitive in
detecting CNS involvement only in the acute
phase, e.g., up to 4 months after the onset of
neurological manifestations. Szer et al. (8)
followed up five children with lupus and
CNS involvement for up to one year after the
onset of symptoms using SPECT, MR and
CT. SPECT showed blood flow abnormali-
ties in all patients, while MR and CT de-
tected anatomical alterations in only three.
In the present study, eight of 19 patients
(42%) presented signs and/or clinical symp-
toms of CNS involvement during the course
of the disease. Six of these eight patients
presented SPECT alterations and only three
showed MR changes. Just one patient pre-
sented clinical manifestations of CNS in-
volvement by the time SPECT and MR were
performed. These data indicate that in some
patients both SPECT and MR remain abnor-
mal even after the acute phase of CNS in-
volvement.
Even though headache is a frequent com-
plaint in lupus patients, its physiopathology
is still unclear. It is plausible to think that
alterations of cerebral blood flow can ex-
plain this symptom. In a study on 19 children
and adolescents with migraine, SPECT
showed hypoperfusion areas in 3/6 patients
with classic migraine and in 1/3 patients
with hemiplegic migraine (15). Steinlin et al.
(6) studied nine JSLE children with head-
ache; four of them were submitted to SPECT
and abnormalities were found in only one. In
our study, we observed SPECT changes in
two patients reporting headache. However,
on the basis of our data and of literature
reports, it is not possible to be sure if SPECT
findings are related to the cause or the conse-
quence of flow alterations.
On the basis of our results, we may con-
clude that a detailed neurological clinical
history continues to be a fundamental tool in
the diagnosis of CNS involvement. SPECT
and MR may be complementary and useful
exams in the evaluation of neurological in-
volvement in lupus.
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